Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.

Ito D, Ikuma-Suwa E, Inoue K, Kaneko K, Yanagisawa M, Inukai K, Noda M, Shimada A.

J Clin Med Res. 2017 Feb;9(2):154-162. doi: 10.14740/jocmr2875w.

PMID:
28090231
2.

Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.

Takase T, Nakamura A, Miyoshi H, Yamamoto C, Atsumi T.

Endocr J. 2016 Dec 13. [Epub ahead of print]

3.

Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.

Nagai Y, Ohta A, Sada Y, Kato H, Tanaka Y.

Expert Opin Pharmacother. 2017 Jan;18(1):13-17. doi: 10.1080/14656566.2016.1261110.

PMID:
27841020
4.
5.

Visualization of mechanism of action, and a further therapeutic potential of ipragliflozin, a selective SGLT2 inhibitor.

Takasu T, Takakura S, Hamada K.

Nihon Yakurigaku Zasshi. 2016;148(5):266-271. No abstract available.

PMID:
27803440
6.

Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.

Kutoh E, Murayama T, Wada A, Hirate M.

Drugs R D. 2016 Dec;16(4):369-376.

7.

Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.

Okajima F, Nagamine T, Nakamura Y, Hattori N, Sugihara H, Emoto N.

J Diabetes Investig. 2016 Oct 20. doi: 10.1111/jdi.12588. [Epub ahead of print]

8.

Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.

Tanaka A, Murohara T, Taguchi I, Eguchi K, Suzuki M, Kitakaze M, Sato Y, Ishizu T, Higashi Y, Yamada H, Nanasato M, Shimabukuro M, Teragawa H, Ueda S, Kodera S, Matsuhisa M, Kadokami T, Kario K, Nishio Y, Inoue T, Maemura K, Oyama J, Ohishi M, Sata M, Tomiyama H, Node K; PROTECT Study Investigators..

Cardiovasc Diabetol. 2016 Sep 13;15(1):133. doi: 10.1186/s12933-016-0449-7.

9.

Predictors of response to ipragliflozin treatment in patients with type 2 diabetes mellitus.

Okada K, Kotani K, Ebihara K, Yamazaki H, Ishibashi S.

Int J Clin Pharmacol Ther. 2016 Dec;54(12):1004-1008.

PMID:
27615008
10.

Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.

Yokote K, Terauchi Y, Nakamura I, Sugamori H.

Expert Opin Pharmacother. 2016 Oct;17(15):1995-2003. doi: 10.1080/14656566.2016.1219341.

PMID:
27477242
11.
12.

Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.

Ishihara H, Yamaguchi S, Nakao I, Okitsu A, Asahina S.

Diabetes Obes Metab. 2016 Dec;18(12):1207-1216. doi: 10.1111/dom.12745.

PMID:
27436788
13.

Fluctuation in Serum Sodium Levels Related to Ipragliflozin Administration in a Patient with Diabetic Nephropathy and Sequela of Traumatic Brain Injury.

Okonogi H, Harada M, Sato H, Tokoro K, Nakayama I, Tsuboi N, Miyazaki Y, Kawamura T, Ogura M, Yokoo T.

Intern Med. 2016;55(14):1887-91. doi: 10.2169/internalmedicine.55.5482.

15.

First case of drug eruption due to ipragliflozin: Case report and review of the literature.

Saito-Sasaki N, Sawada Y, Nishio D, Nakamura M.

Australas J Dermatol. 2016 May 31. doi: 10.1111/ajd.12502. [Epub ahead of print]

PMID:
27242192
16.

[Efficacy of Ipragliflozin in Patients with Steroid-Induced Hyperglycemia during Cancer Chemotherapy].

Horasawa S, Osame K, Kawasumi K, Saito S, Bando H, Ohashi K.

Gan To Kagaku Ryoho. 2016 May;43(5):645-7. Japanese.

PMID:
27210101
17.

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.

Kashiwagi A, Yoshida S, Nakamura I, Kazuta K, Ueyama E, Takahashi H, Satomi H, Kosakai Y, Kawamuki K.

J Diabetes Investig. 2016 Jul;7(4):544-54. doi: 10.1111/jdi.12471.

18.

Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.

Iemitsu K, Iizuka T, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Obana M, Sasai N, Kaneshige H, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I.

J Clin Med Res. 2016 May;8(5):373-8. doi: 10.14740/jocmr2492w.

19.

Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes.

Kutoh E, Wada A, Murayama T, Hirate M.

Drug Res (Stuttg). 2016 Jul;66(7):345-50. doi: 10.1055/s-0035-1569454.

PMID:
27056638
20.

Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.

Yamamoto C, Miyoshi H, Ono K, Sugawara H, Kameda R, Ichiyama M, Yamamoto K, Nomoto H, Nakamura A, Atsumi T.

Endocr J. 2016 Jun 30;63(6):589-96. doi: 10.1507/endocrj.EJ15-0749.

Items per page

Supplemental Content

Loading ...
Support Center